1. Scrip
  2. >>Drug Pricing

Adherence Issues Add Weight To Digital Trials Push

 
• By Lubna Ahmed

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Luminous man
Can digital-based trials improve patient adherence to medicines?

Companies like GlaxoSmithKline PLC, Bayer AG, Novartis AG, AstraZeneca PLC and Teva Pharmaceutical Industries Ltd., are extending their hands to those in the technology industry, establishing partnerships to explore this uncharted area. From developing wearables and applications to building portals to gather data, pharma is exploring the usability of tech in R&D processes.

GSK's head of digital innovation and strategic partnerships, AJ Ploszay, told Scrip, "The capabilities a pharmaceutical company now needs are not organically found within a traditional company." He emphasized that...

There is enormous potential for digital technology in clinical trials, says ICON PLC's director of product innovation, Marie McCarthy. She believes new technologies, like apps on mobiles and other handheld...

More from Drug Pricing

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.